title: A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
abstract: BACKGROUND
  Previous studies have demonstrated an association between genetic polymorphisms of the mu opioid receptor gene (OPRM1) and response to naltrexone treatment. The Asp40 variant genotype previously shown to be associated with naltrexone treatment response is known to be relatively common among Koreans.
  
  
  OBJECTIVE
  This study was conducted to prospectively investigate the relationship between genotype and response to open-label naltrexone treatment in Korean alcohol-dependent subjects.
  
  
  METHODS
  Sixty-three alcohol-dependent subjects were prescribed naltrexone for 12 weeks in combination with cognitive behavioral therapy. Thirty-two subjects were adherent, taking the medication at least 80% of the treatment days [16 Asn40 (A/A) patients and 16 Asp40 variant (A/G or G/G) patients].
  
  
  RESULTS
  Subjects adherent to naltrexone treatment with one or two copies of the Asp40 allele took a significantly longer time than the Asn40 group to relapse (p=0.014). Although not significant, the Asn40 group treated with naltrexone had a 10.6 times greater relapse rate than the Asp40 variant group. There was no significant difference between the Asn40 group and the Asp40 variant group treated with naltrexone in rates of abstinence.
  
  
  CONCLUSIONS
  These results demonstrating a higher therapeutic effect of naltrexone in Korean alcohol-dependent individuals with the Asp40 variant genotype than the Asn40 genotype are consistent with previous study results in individuals of European descent. This is the first study to examine the pharmacogenetics treatment response to naltrexone in non-European subjects.
authors.affiliation: Department of Psychiatry, School of Medicine, Pusan National University, and Bongseng Memorial Hospital, 1-ga 10, Ami-dong, Seo-gu, Pusan, 602-739, South Korea. sungkim@pusan.ac.kr
authors.forename: Sung-Gon
authors.initials: SG
authors.lastname: Kim
authors.forename: Cheol-Min
authors.initials: CM
authors.lastname: Kim
authors.forename: Sam-Wook
authors.initials: SW
authors.lastname: Choi
authors.forename: Young-Myo
authors.initials: YM
authors.lastname: Jae
authors.forename: Hae-Gook
authors.initials: HG
authors.lastname: Lee
authors.forename: Bong-Ki
authors.initials: BK
authors.lastname: Son
authors.forename: Jeong-Gee
authors.initials: JG
authors.lastname: Kim
authors.forename: Young-Sung
authors.initials: YS
authors.lastname: Choi
authors.forename: Han-Oh
authors.initials: HO
authors.lastname: Kim
authors.forename: Seong-Yeon
authors.initials: SY
authors.lastname: Kim
authors.forename: David W
authors.initials: DW
authors.lastname: Oslin
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000188:drug therapy* / Q000235:genetics / Q000534:rehabilitation; D000483:Alleles; D044466:Asian People / Q000235:genetics; D015928:Cognitive Behavioral Therapy; D005260:Female; D006801:Humans; D007723:Korea; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D017450:Receptors, Opioid, mu / Q000235:genetics*; D012008:Recurrence; D013695:Temperance
chemical_list: D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D009271:Naltrexone
references.citation: Alcohol Alcohol. 2000 Nov-Dec;35(6):587-93
references.pmid: 11093966
references.citation: J Neurochem. 1992 Jul;59(1):157-63
references.pmid: 1613496
references.citation: Alcohol Alcohol. 1996 Mar;31 Suppl 1:13-6
references.pmid: 8736996
references.citation: Pharmacogenet Genomics. 2006 Sep;16(9):625-36
references.pmid: 16906017
references.citation: Alcohol Clin Exp Res. 2008 Jul;32(7):1113-23
references.pmid: 18540916
references.citation: Mol Psychiatry. 1999 Sep;4(5):476-83
references.pmid: 10523821
references.citation: Eur Neuropsychopharmacol. 2007 Jul;17(8):558-66
references.pmid: 17379484
references.citation: Alcohol. 1989 Jan-Feb;6(1):59-63
references.pmid: 2524202
references.citation: Addiction. 2001 Nov;96(11):1565-73
references.pmid: 11784454
references.citation: Pharmacogenomics J. 2007 Oct;7(5):353-61
references.pmid: 17224915
references.citation: Mol Psychiatry. 1997 Oct-Nov;2(6):490-4
references.pmid: 9399694
references.citation: Biochem Genet. 1993 Aug;31(7-8):321-8
references.pmid: 8274138
references.citation: Am J Psychiatry. 1995 Apr;152(4):613-5
references.pmid: 7694913
references.citation: Alcohol Alcohol. 1996 Mar;31 Suppl 1:33-42
references.pmid: 8736999
references.citation: Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47
references.pmid: 11707638
references.citation: J Clin Psychopharmacol. 2001 Feb;21(1):72-7
references.pmid: 11199951
references.citation: Arch Gen Psychiatry. 2007 Sep;64(9):1069-77
references.pmid: 17768272
references.citation: Pharmacogenomics J. 2004;4(3):184-92
references.pmid: 15007373
references.citation: Arch Gen Psychiatry. 2008 Feb;65(2):135-44
references.pmid: 18250251
references.citation: Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13
references.pmid: 9689128
references.citation: Pharmacogenetics. 2002 Jan;12(1):3-9
references.pmid: 11773859
references.citation: J Biol Chem. 2005 Sep 23;280(38):32618-24
references.pmid: 16046395
references.citation: Biol Psychiatry. 2007 Jun 1;61(11):1244-51
references.pmid: 17157823
references.citation: Neuropsychopharmacology. 2000 May;22(5):493-503
references.pmid: 10731624
references.citation: Psychopharmacology (Berl). 2006 Oct;188(3):355-63
references.pmid: 16960700
references.citation: Acta Anaesthesiol Scand. 2004 Nov;48(10):1232-9
references.pmid: 15504181
references.citation: Psychopharmacology (Berl). 1997 Jan;129(1):15-22
references.pmid: 9122358
references.citation: Am J Geriatr Psychiatry. 1997 Fall;5(4):324-32
references.pmid: 9363289
references.citation: Alcohol Clin Exp Res. 2007 Jan;31(1):1-10
references.pmid: 17207095
references.citation: Alcohol Clin Exp Res. 2007 Apr;31(4):555-63
references.pmid: 17374034
references.citation: Exp Clin Psychopharmacol. 2007 Jun;15(3):272-81
references.pmid: 17563214
references.citation: Behav Neurosci. 2006 Dec;120(6):1218-24
references.pmid: 17201465
references.citation: Neuropsychopharmacology. 2003 Aug;28(8):1546-52
references.pmid: 12813472
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2003 Apr 1;118B(1):60-5
references.pmid: 12627468
references.citation: Arch Gen Psychiatry. 1992 Nov;49(11):876-80
references.pmid: 1345133
references.citation: Alcohol Clin Exp Res. 2004 Jul;28(7):986-90
references.pmid: 15252283
references.citation: Neuropharmacology. 1982 Jun;21(6):487-97
references.pmid: 6287334
references.citation: N Engl J Med. 2001 Dec 13;345(24):1734-9
references.pmid: 11742047
references.citation: Alcohol Clin Exp Res. 2004 Dec;28(12):1789-95
references.pmid: 15608594
references.citation: Alcohol Clin Exp Res. 1998 Dec;22(9):2108-10
references.pmid: 9884158
references.citation: Acta Anaesthesiol Scand. 2006 Aug;50(7):787-92
references.pmid: 16879459
references.citation: Arch Gen Psychiatry. 1992 Nov;49(11):881-7
references.pmid: 1444726
references.citation: Am J Addict. 2001 Summer;10(3):258-68
references.pmid: 11579624
references.citation: Neuropsychopharmacology. 2002 Jan;26(1):106-14
references.pmid: 11751037